KR20190060786A - 갑상선-관련 부작용을 감소시키는 방법 - Google Patents

갑상선-관련 부작용을 감소시키는 방법 Download PDF

Info

Publication number
KR20190060786A
KR20190060786A KR1020197010782A KR20197010782A KR20190060786A KR 20190060786 A KR20190060786 A KR 20190060786A KR 1020197010782 A KR1020197010782 A KR 1020197010782A KR 20197010782 A KR20197010782 A KR 20197010782A KR 20190060786 A KR20190060786 A KR 20190060786A
Authority
KR
South Korea
Prior art keywords
optionally substituted
days
alkyl
group
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197010782A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 리안
히로코 마사무네
마크 에리온
브루스 이토
Original Assignee
바이킹 테라퓨틱스 인코포레이티드
메타베이시스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이킹 테라퓨틱스 인코포레이티드, 메타베이시스 테라퓨틱스, 인크. filed Critical 바이킹 테라퓨틱스 인코포레이티드
Priority to KR1020247016178A priority Critical patent/KR20240074912A/ko
Publication of KR20190060786A publication Critical patent/KR20190060786A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197010782A 2016-09-16 2017-09-13 갑상선-관련 부작용을 감소시키는 방법 Ceased KR20190060786A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247016178A KR20240074912A (ko) 2016-09-16 2017-09-13 갑상선-관련 부작용을 감소시키는 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662396025P 2016-09-16 2016-09-16
US201662396015P 2016-09-16 2016-09-16
US62/396,015 2016-09-16
US62/396,025 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016178A Division KR20240074912A (ko) 2016-09-16 2017-09-13 갑상선-관련 부작용을 감소시키는 방법

Publications (1)

Publication Number Publication Date
KR20190060786A true KR20190060786A (ko) 2019-06-03

Family

ID=61619247

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197010782A Ceased KR20190060786A (ko) 2016-09-16 2017-09-13 갑상선-관련 부작용을 감소시키는 방법
KR1020247016178A Pending KR20240074912A (ko) 2016-09-16 2017-09-13 갑상선-관련 부작용을 감소시키는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247016178A Pending KR20240074912A (ko) 2016-09-16 2017-09-13 갑상선-관련 부작용을 감소시키는 방법

Country Status (9)

Country Link
US (1) US20190255080A1 (https=)
EP (1) EP3512523A4 (https=)
JP (2) JP2019531346A (https=)
KR (2) KR20190060786A (https=)
CN (2) CN121695155A (https=)
AU (1) AU2017327383B2 (https=)
CA (1) CA3037146A1 (https=)
MX (2) MX2019003032A (https=)
WO (1) WO2018053036A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2020225736A1 (en) * 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
AU2020334943A1 (en) 2019-08-19 2022-03-10 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
JP7670687B2 (ja) * 2020-02-24 2025-04-30 へパジーン セラピューティクス （エイチケイ） リミテッド 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP1525219B1 (en) * 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
WO2006128058A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
JP6013736B2 (ja) * 2008-12-22 2016-10-25 オトノミ—，インク． 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
US20170319604A1 (en) * 2016-04-22 2017-11-09 Metabasis Therapeutics, Inc. Thyroid hormone receptor agonist and use thereof
CA3044059A1 (en) * 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease

Also Published As

Publication number Publication date
JP2019531346A (ja) 2019-10-31
MX2023000887A (es) 2023-02-22
JP2022174261A (ja) 2022-11-22
NZ751857A (en) 2024-05-31
CN109922812A (zh) 2019-06-21
MX2019003032A (es) 2019-09-13
JP7656574B2 (ja) 2025-04-03
CA3037146A1 (en) 2018-03-22
WO2018053036A1 (en) 2018-03-22
EP3512523A1 (en) 2019-07-24
AU2017327383A1 (en) 2019-04-11
AU2017327383B2 (en) 2023-06-29
EP3512523A4 (en) 2020-05-06
BR112019005039A2 (pt) 2019-06-25
KR20240074912A (ko) 2024-05-28
CN121695155A (zh) 2026-03-20
US20190255080A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
JP7656574B2 (ja) 甲状腺関連副作用を低下させる方法
KR20210099612A (ko) 간 장애의 치료를 위한 조성물 및 방법
JP5291700B2 (ja) 血管新生阻害薬及び使用方法
EP2786750B2 (en) Agent for reducing adverse side effects of kinase inhibitor
KR20190104524A (ko) 당원축적질환의 치료 방법
KR101516677B1 (ko) 지방성 간 질환의 치료용 의약 조성물
JP2023526567A (ja) バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法
EP2752190B1 (en) Method for improving therapy for autoimmune diseases such as rheumatoid arthritis
JP7146281B2 (ja) 経鼻投与用医薬組成物
JPH06279397A (ja) アミノ酸系末梢神経障害改善剤
RU2850978C1 (ru) Применение агониста рецептора сфингозин-1-фосфата
WO2020092376A1 (en) Treating non-alcoholic steatohepatitis (nash)
EP4316489A1 (en) Therapeutic agent for gait disturbance
JP6875747B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
JP6935930B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
KR20030087051A (ko) 아릴에텐술폰아미드 유도체의 신규한 용도
KR20070102694A (ko) 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
JPH1045666A (ja) 血糖低下剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104